PHILADELPHIA, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced that the company will accelerate its experimental program for a new intranasal influenza vaccine combination following a media briefing by the Centers for Disease Control (CDC) urging Americans, especially young children and the elderly, to get vaccinated for the emerging flu season immediately (CDC, December 12, 2013), coincidental with National Influenza Vaccination Week.
Centers For Disease Control Urges Preparation For An Active Seasonal Flu Season
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.